AT-01 Archives | Attralus

Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

Jan 15, 2025 Press Releases

PDF Version Phase 3 – REVEAL study for iodine 124I-evuzamitide (AT-01) in patients with suspected cardiac amyloidosis has begun enrollment by Brigham and Women’s Hospital, Boston MA, in conjunction with Attralus. Attralus is developing 124I-evuzamitide as the first...

Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

Aug 5, 2024 Press Releases

PDF Version 124I-evuzamitide (AT-01) is one of the first investigational diagnostic imaging agents to receive Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA), and the only diagnostic imaging agent that has received BTD for cardiac...

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)

May 30, 2024 Press Releases

PDF Version AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis patients to support its use as an immunotherapy in patients...

Utilizing 124I-Evuzamitide PET/MRI to Elucidate the Relationship between Renal Dysfunction and Amyloid Deposition in Transthyretin Amyloid Cardiomyopathy

May 28, 2024 Posters & Publications

Click Here to View...

Uptake of Iodine (124I) Evuzamitide in Patients with AL and ATTR Amyloidosis and Correlation with Echocardiographic Parameters